Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study

S. K. Williamson, J. J. Crowley, Robert B Livingston, T. J. Panella, J. W. Goodwin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalInvestigational New Drugs
Volume13
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

fazarabine
Non-Small Cell Lung Carcinoma
Costs and Cost Analysis
Health Care Costs
Drug Therapy
Investigational Therapies
Etoposide
Therapeutics
Nucleosides
Confidence Intervals

Keywords

  • Cost analysis
  • Fazarabine
  • Lung neoplasms
  • Nucleosides

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung : A Southwest Oncology Group Study. / Williamson, S. K.; Crowley, J. J.; Livingston, Robert B; Panella, T. J.; Goodwin, J. W.

In: Investigational New Drugs, Vol. 13, No. 1, 1995, p. 67-71.

Research output: Contribution to journalArticle

@article{44939cbe4d1f4eef95ec02cfdddfce8f,
title = "Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study",
abstract = "Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0{\%}, 95{\%} confidence interval = 0-15{\%}) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.",
keywords = "Cost analysis, Fazarabine, Lung neoplasms, Nucleosides",
author = "Williamson, {S. K.} and Crowley, {J. J.} and Livingston, {Robert B} and Panella, {T. J.} and Goodwin, {J. W.}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "67--71",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung

T2 - A Southwest Oncology Group Study

AU - Williamson, S. K.

AU - Crowley, J. J.

AU - Livingston, Robert B

AU - Panella, T. J.

AU - Goodwin, J. W.

PY - 1995

Y1 - 1995

N2 - Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.

AB - Background: Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods: Twenty-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions: Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.

KW - Cost analysis

KW - Fazarabine

KW - Lung neoplasms

KW - Nucleosides

UR - http://www.scopus.com/inward/record.url?scp=0029157676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029157676&partnerID=8YFLogxK

M3 - Article

C2 - 7499111

AN - SCOPUS:0029157676

VL - 13

SP - 67

EP - 71

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -